Celldex Therapeutics SVPs Engage In Heavy Transactions [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
This transaction represented 11.92% of his direct holdings at the time, reducing his direct stake from 34,962 to 30,796 shares. The sale was executed entirely in direct ownership, with no involvement of indirect entities or derivative securities. These 10 stocks could mint the next wave of millionaires › On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX) , executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing Metric Value Shares sold (direct) Transaction value Post-transaction shares (direct) Post-transaction value (direct ownership) Transaction value based on SEC Form 4 reported price ($29.09); post-transaction value based on Dec. 4, 2025 market close ($29.09). How does the size of this sale compare to Jimenez's historical selling activity? This sale of 4,166 shares is larger than his only other recent open-market sale (771 shares on Aug. 13, 2025) and exceeds the recent medi
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- MoneyShow's Best Investment Ideas For 2026: Part 3 [Seeking Alpha]Seeking Alpha
- Barclays Lifts PT on Celldex Therapeutics (CLDX) to $24 From $21 [Yahoo! Finance]Yahoo! Finance
- We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics (NASDAQ:CLDX) had its price target raised by analysts at Barclays PLC from $21.00 to $24.00. They now have an "underweight" rating on the stock.MarketBeat
- Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic DermographismGlobeNewswire
CLDX
Earnings
- 11/10/25 - Miss
CLDX
Sec Filings
- 1/6/26 - Form 4
- 12/17/25 - Form 4
- 12/8/25 - Form 4
- CLDX's page on the SEC website